Compared with the limited efficacy of traditional chemo- and radiotherapy in combination with surgery, molecular targeted chemicals, particularly EGFR tyrosine kinase inhibitors (TKIs), have emerged as potent anticancer agents and have significantly improved the prognosis of lung cancer patients with EGFR mutations [2]. The gene discussed is EGFR; the disease is lung carcinoma.